Literature DB >> 30187870

[Correlation of apolipoprotein AI, apolipoprotein B and their ratio with the severity of cerebral white matter lesions].

Weihua Huang1, Tianming Lv1, Huanmin Li1, Shuhua Du1, Canhong Yang1, Shiqi Yuan1.   

Abstract

OBJECTIVE: To investigate the correlation of apolipoprotein AI (ApoAI), ApoB, ApoB/ApoAI and the severity of brain white matter lesions (WML).
METHODS: A total of 648 patients with WML confirmed by brain magnetic resonance imaging (MRI) were divided into mild WML group (n=386) and moderate to severe WML group (n=262) according to evaluations with the Fazekas scale. The demographic data, blood biochemical parameters and the levels of ApoAI, ApoB and ApoB/AI ratio were compared between the two groups to identify the risk factors of moderate to severe WML.
RESULTS: Univariate analysis showed that age, gender, hypertension, diabetes, coronary heart disease, previous stroke, homocysteine, HDL-C, ApoAI, and ApoB/AI ratio all differed significantly between the two groups (P < 0.05), but ApoB levels were similar between them (P > 0.05). Multivariate logistic regression analysis revealed that with ApoAI and ApoB/AI ratio as the continuous variables, after adjustment for the compounding factors, ApoB/AI ratio was an independent risk factor (OR=11.456, 95% CI: 3.622-36.229, P < 0.001) and ApoAI was an independent protective factor for moderate to severe WML (OR=0.068, 95% CI: 0.018-0.262, P < 0.001). With the upper quartiles of ApoAI level (1.38 g/L) and ApoB/AI ratio (0.58) as their respective cutoff values, patients with a high ApoAI level and a low ApoB/AI ratio were found to have the lowest incidence of moderate to severe WML (P < 0.001).
CONCLUSIONS: An increased ApoB/AI ratio is an independent risk factor and an increased ApoAI level is an independent protective factor for moderate to severe WML.

Entities:  

Keywords:  apolipoprotein AI; apolipoprotein B; protective factors; risk factors; white matter lesions

Mesh:

Substances:

Year:  2018        PMID: 30187870      PMCID: PMC6744045          DOI: 10.3969/j.issn.1673-4254.2018.08.15

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  30 in total

1.  Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study.

Authors:  José R Romero; Alexa Beiser; Sudha Seshadri; Emelia J Benjamin; Joseph F Polak; Ramachandran S Vasan; Rhoda Au; Charles DeCarli; Philip A Wolf
Journal:  Stroke       Date:  2009-03-05       Impact factor: 7.914

2.  To help save the heart, is it time to retire cholesterol tests?

Authors:  Mitch Leslie
Journal:  Science       Date:  2017-12-08       Impact factor: 47.728

3.  Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study.

Authors:  Ophélia Godin; Christophe Tzourio; Pauline Maillard; Bernard Mazoyer; Carole Dufouil
Journal:  Circulation       Date:  2011-01-10       Impact factor: 29.690

4.  C-reactive Protein Level, Apolipoprotein B-to-apolipoprotein A-1 Ratio, and Risks of Ischemic Stroke and Coronary Heart Disease among Inner Mongolians in China.

Authors:  Yun Fan Tian; Yi Peng Zhou; Chong Ke Zhong; Batu Buren; Tian Xu; Hong Mei Li; Ming Zhi Zhang; Ai Li Wang; Yong Hong Zhang
Journal:  Biomed Environ Sci       Date:  2016-07       Impact factor: 3.118

5.  Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people.

Authors:  Alison D Murray; Roger T Staff; Susan D Shenkin; Ian J Deary; John M Starr; Lawrence J Whalley
Journal:  Radiology       Date:  2005-08-26       Impact factor: 11.105

6.  The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor.

Authors:  Chongren Tang; Yuhua Liu; Peter S Kessler; Ashley M Vaughan; John F Oram
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

7.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging.

Authors:  F Fazekas; J B Chawluk; A Alavi; H I Hurtig; R A Zimmerman
Journal:  AJR Am J Roentgenol       Date:  1987-08       Impact factor: 3.959

8.  The apolipoprotein B/A1 ratio is associated with reactive oxygen metabolites and endothelial dysfunction in statin-treated patients with coronary artery disease.

Authors:  Takuo Emoto; Takahiro Sawada; Natsumi Morimoto; Takako Tenjin; Taku Wakimoto; Fumie Ikeda; Chiaki Sato; Daisuke Terashita; Taiji Mizoguchi; Takao Mizuguchi; Hiroshi Okamoto; Yosuke Matsuo; Sushi-Ku Kim; Akira Takarada; Mitsuhiro Yokoyama
Journal:  J Atheroscler Thromb       Date:  2013-05-10       Impact factor: 4.928

9.  Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals.

Authors:  Fei Song; Anne Poljak; John Crawford; Nicole A Kochan; Wei Wen; Barbara Cameron; Ora Lux; Henry Brodaty; Karen Mather; George A Smythe; Perminder S Sachdev
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

10.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Authors:  Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

View more
  1 in total

1.  Improvement of Total Flavonoids from Dracocephalum moldavica L. in Rats with Chronic Mountain Sickness through 1H-NMR Metabonomics.

Authors:  Atiguli Maimaiti; Yang Tao; Wang Minmin; Miao Weiwei; Shi Wenhui; Ainiwaer Aikemu; Dilinuer Maimaitiyiming
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.